Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Wall Street Analysts Forecast Growth
Separately, Roth Capital lowered their price target on shares of Viking Therapeutics from $20.00 to $15.00 in a research report on Thursday, April 28th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.50.
Viking Therapeutics Trading Down 4.5 %
NASDAQ:VKTX traded down $0.16 during midday trading on Tuesday, reaching $3.41. 348,547 shares of the stock traded hands, compared to its average volume of 1,109,677. Viking Therapeutics has a 12-month low of $2.02 and a 12-month high of $7.20. The business has a 50-day moving average of $2.89 and a two-hundred day moving average of $2.96.